Drug intelligence / Profile preview

SatiPurple

Development stage: Unknown
Lead developer: Harvest One
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral, Inhalation

Overview

**SatiPurple** is a high-CBD medical cannabis product from the Satipharm brand, color-coded to indicate its position at the high CBD end of a THC-CBD continuum ranging from SatiWhite (high THC) to SatiPurple (high CBD). Developed as part of a standardized product line for medical use, it is indoor-grown cannabis intended to assist consumers in making informed choices for health and wellness applications, supplied through partnerships like Shoppers Drug Mart in Canada.[3][4][8]

Brand names: SatiPurple

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on SatiPurple.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SatiPurple.

Explore the full profile